Dr. Michael Schwartz is featured in an interview by the American Society for Clinical Investigation (ASCI), published on September 10, 2014. The focus of The ASCI Interviews series is to provide the American public with a better understanding of how federal taxes support medical advances. Click here for the full transcript of the interview. Dr. Schwartz is the RH Williams Endowed Chair, Director of the Diabetes and Obesity Center of Excellence and a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition.
Dr. Joshua Thaler has been awarded an NIH R03 for his project entitled “Glial-neuronal metabolic coupling in obesity”. This proposal focuses on lactate signaling between hypothalamic astrocytes and neurons. The data obtained from these investigations will form the basis of a new line of research centered on glial-neuronal metabolic coupling as a novel obesity target. Dr. Thaler is an Assistant Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition.
Dr. Joshua Thaler is one of 5 recipients awarded a Pathway to Stop Diabetes Accelerator Award from the American Diabetes Association. This 5-year, $1.625 million grant entitled ” Modulating glial-neuronal interactions to treat obesity and diabetes” explores the possibility that glial cells (the brain’s damage response cells) in the hypothalamus area of the brain play an important part in the process of becoming obese and developing diabetes. Accelerator Awards are granted to early-career diabetes investigators pursuing high risk but promising projects. Dr. Thaler is an Assistant Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition. Click here for more information about this year’s award recipients.
Dr. Michael Schwartz has been awarded a 4-year NIH R01 for his project “ Novel Brain Mechanisms Controlling Glucose Homeostasis”. This project is based upon recently published evidence from the Schwartz Laboratory that the brain can rapidly, potently and selectively increase insulin-independent glucose lowering. The overarching goals are to employ state-of-the-art methods of metabolic analysis in defined mouse models to 1) more clarify how these centrally mediated effects are mediated and identify the humoral signals that activate them, 2) delineate peripheral mechanisms of glucose lowering, and 3) establish their physiological relevance. Dr. Schwartz is the RH Williams Endowed Chair in Medicine, Division of Metabolism, Endocrinology and Nutrition.
DOCE Associate Director Karin Bornfeldt, PhD is senior author of an article published in the April issue of Cell Reports (Cell Press). This article, entitled “Testing the Role of Myeloid Cell Glucose Flux in Inflammation and Atherosclerosis”, demonstrates that increased glucose flux in macrophages and other myeloid cells does not contribute to inflammation and atherosclerosis in vivo. These findings have important implications for studies on diabetic vascular disease; a multifactorial disease in which the role of glucose is still uncertain. The article was also featured in the April 10th issue of Cell Reports: “Getting to the cardiovascular heart of diabetes: Q&A with Karin Bornfeldt”. DOCE researcher Jenny Kanter, PhD, is co-author on the article.
DOCE Director Michael Schwartz, MD, has been selected to give the 7th Annual Levi J. Hammond Distinguished Memorial Lecture. This annual lecture was held at the University of Pennsylvania on May 13, 2014.
DOCE Director Michael Schwartz, MD, is senior author on a review article published in the May issue of Nature Review Neuroscience. The article entitled “Neurobiology of food intake in health and disease” highlights how the interplay between homeostatic and emergency feeding circuits influences the biologically defended level of body weight under physiological and pathophysiological conditions. DOCE researchers Gregory Morton, PhD is first author and Thomas Meek, PhD is co-author.
Dr. Karin Bornfeldt, PhD, has been awarded the 2014 Edwin Bierman Lectureship. The lecture will be delivered at the American Diabetes Association’s Annual Sessions in San Francisco, June 16th. The award and lecture recognize a leading scientist in the field of macrovascular complications and contributing risk factors in diabetes. Click here for more information. Dr. Bornfeldt is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition and Professor of Pathology.
DOCE Director Dr. Michael Schwartz has been awarded a 5-year NIH R01 for his project “Novel Anti-Diabetic Actions of Hypothalamic FGF19-FGFR1 Signaling”. The proposal stems from the finding by the Schwartz laboratory that FGF19 action in the brain rapidly, potently and selectively increases insulin-independent glucose disposal identifies a novel, CNS-driven mechanism with translational implications for both the pathogenesis and treatment of human diabetes. Studies in this proposal seek to clarify how this occurs and the extent to which it explains the anti-diabetic effect of bariatric surgical procedures.
DOCE Associate Director Karin Bornfeldt, PhD, Awarded 2013 Russell Ross Memorial Lectureship in Vascular Biology
Dr. Karin Bornfeldt, PhD, has been awarded the 2013 Russell Ross Memorial Lectureship in Vascular Biology. The lecture was delivered at the American Heart Association’s Annual Sessions in Dallas on November 19th. The Ross Lecture is one of three ATVB named lectures presented annually at the American Heart Association’s Scientific Sessions. The lectureship is named after Dr. Russell Ross, Professor and former Chair of Pathology at the UW. Dr. Bornfeldt is a Professor of Medicine in the Division of Metabolism, Endocrinology and Nutrition and Professor of Pathology.